What are the advantages to using private practices, as opposed to academic institutions, for testing medications? Dr. Allen Verne, president of the American Retina Foundation and founder of the Bay Area Retina Associates, discusses in-office drug studies he is involved in, including one on diabetic retinopathy and another on photodynamic therapy, and why these studies can be particularly useful in determining the most effective treatments for patients with retinal conditions. Dr. Verne also discusses the process of separating the interests of the pharmaceutical companies sponsoring studies and those participating in the study. What are the financial and time costs to the practices involved in in-office medication studies? Dr. Roy Levit hosts.
In-Office Drug Testing for Retinal Conditions
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
What are the advantages to using private practices, as opposed to academic institutions, for testing medications? Dr. Allen Verne, president of the American Retina Foundation and founder of the Bay Area Retina Associates, discusses in-office drug studies he is involved in, including one on diabetic retinopathy and another on photodynamic therapy, and why these studies can be particularly useful in determining the most effective treatments for patients with retinal conditions. Dr. Verne also discusses the process of separating the interests of the pharmaceutical companies sponsoring studies and those participating in the study. What are the financial and time costs to the practices involved in in-office medication studies? Dr. Roy Levit hosts.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
FCS and SHTG: Are We Meeting the Need?
A Multidisciplinary Exploration of Complexities and Controversies in Thyroid Eye Disease: Spotlight on Diagnosis
Updates From the 7th World Symposium Task Force
Selecting the Optimal ICI Partner for First-Line Treatment of Unresectable HCC: CTLA-4 vs VEGF Inhibitors
Integrating Guideline Directed Medical Therapy for Patients with CKD and T2D
Challenges of managing hyperkalemia in patients with cardiorenal disease while maintaining RAASi therapy
Antibody-Drug Conjugates in Bladder Cancer: Guideline Updates and Adverse Event Management
Exploring New and Emerging Treatments in Muscle Invasive Bladder Cancer
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?